Christine Blank

Express Scripts will manage pharmacy benefits for about 20 million Centene members.

Durability and toxicities such as cytokine release syndrome and immune effector-cell neurotoxicity syndrome are among the challenges.

Regulators have approved Imjudo, a monoclonal antibody that targets the activity CTLA-4, to be used in combination with Imfinzi, a PD-L1 inhibitor.

The study looked at cancer patients as a group, but senior author notes that ‘that treatments for blood cancers are very costly and many of them require treatment for long periods of time.’

Novavax’ protein-based vaccine is engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease.

Arash Sadeghi, Pharm.D., discusses three drugs in development, which treat a rare kidney disease, hemophilia B, and an advanced form of age-related macular degeneration.

The lack of competition and the vertical integration of PBMs and insurers can have a negative impact on patients’ access to and cost of prescription drugs, AMA said.

Until supply is restored, the FDA suggests the use of alternatives such as the extended-release version of amphetamine mixed salts.

Findings may support the development of an aerobic exercise training intervention for people with multiple sclerosis (MS) who present with MS-related thalamic atrophy.

The FDA had indicated that it would not issue an emergency use authorization without additional data for peginterferon lambda to treat patients with mild-to-moderate COVID-19.

SIGA indicated that $5.1 million of oral Tpoxx is targeted for delivery in 2022.

The retailer indicated that Express Scripts’ drug pricing model is unstainable for Kroger and its customers.

In 2021, patients in the United States received 6.4 billion prescriptions, 91% of which were generic and biosimilar medicines.

Bebtelovimab is available under an emergency use authorization, and the HHS is making doses available to those who are uninsured and underinsured.

An Avalere review finds that the proportion of generic drugs covered on lower tiers (with generally lower out-of-pocket costs for patients) in Part D plans have decreased.

World Health Organization said there is a lack of evidence of clinical effectiveness of the monoclonal antibodies Xevudy and Regen-Cov against the COVID-19 variants that are currently circulating.

A Texas judge ruled that coverage for HIV pre-exposure prophylaxis (PrEP) violates religious freedom but there is concern that cancer screenings and other preventive services could be affected.

Research conducted in Canada suggests that people with multiple sclerosis would benefit from being seen by nurse practitioners. However, secondary outcomes in the study did not improve among patients with access to nurse practitioner-led care.

HHS is providing $11 million to Grand River Aseptic Manufacturing to accelerate manufacturing of the Jynneos monkeypox vaccine. The facility will be operational later this year.

Labor shortages and Drug Enforcement Agency quotas have led to supply shortages of Adderall and its generics, which are used to treat attention deficit hyperactivity disorder.

Payer coverage and the prior authorization process continue to be barriers for the adoption of biosimilars, according to a new Vizient survey.

The FDA has assigned a Prescription Drug User Fee Act action date of June 16, 2023.

The rate reflects a continued trend toward moderation of the overall increase in drug prices.

Sean Dickson of West Health Policy Center discusses Reuters' analysis of drug launch prices.

The researchers attributed low adherence to oral anti-cancer medications for blood cancer and certain other cancers to high monthly out-of-pocket among several other reasons.

Researchers report that half of the online pharmacies are rogue operations that may operate without a license or have other serious shortcomings.

The EUA allows Jynneos to be used in children at high risk for monkeypox and as an intradermal injection, rather than subcutaneous, for adults.

A rise in the number of long COVID is sparking research efforts by the HHS, the CDC and drug companies to understand the conditions and develop treatments.

Confirmed cases of monkeypox in the United States have reached more than 7,500, according to the CDC.

OptumRx profiles four therapies that are expecting FDA decisions in the next few months.